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Abstract The purpose of this study was to evaluate
concentrated autologous bone marrow aspirate transplanta-
tion (CABMAT) treatment for corticosteroid-induced osteo-
necrosis of the femoral head (ONFH) in systemic lupus
erythematosus (SLE). Bone marrow was aspirated from
iliac crests, concentrated on a conventional manual blood
bag centrifugation technique that is used to extract buffy
coats and then injected into nine hips with drilling. The
mean number of nucleated cells for transplantation was
5.32×10
7 cells/ml. This cell concentration was significantly
higher after concentration, and the mean concentration ratio
was 5.5. At follow-up (minimum: three years), significant
improvement in pain and Harris Hip Score was observed.
For eight of nine hips, we successfully preserved the
femoral head. However, one hip required total hip arthro-
plasty 45 months after the operation. CABMAT using our
centrifugation technique is an effective, safe and low-cost
procedure of therapeutic osteogenesis for corticosteroid-
induced ONFH in SLE.
Introduction
Systemic lupus erythematosus (SLE) is a chronic, inflam-
matory, multisystem autoimmune disease of unknown
aetiology that predominantly affects young people [1].
Osteonecrosis (ON) is a common musculoskeletal compli-
cation in SLE with high-dose corticosteroid therapy [2]. In
Japan, approximately 54% of patients with idiopathic ON
of the femoral head (ONFH) have received corticosteroid
therapy and 31% of patients with corticosteroid-induced
ONFH have SLE [3]. The clinical course of ON is
unpredictable, but radiographic evaluation has demonstrat-
ed that small osteonecrotic lesions may heal, remain stable
without progression or eventually cause significant joint
damage [4]. However, large lesions, even those that are
asymptomatic, may result in femoral head collapse and pain
from the fracture and secondary osteoarthritis [5].
It has been reported that failed or delayed fracture healing
and ONFH can be repaired with autologous bone marrow
aspirate (BMA) transplantation [6, 7]. Hernigou et al. [8]f i r s t
reported the results of a prospective study on the benefits of
autologous bone marrow grafting. Gangji et al. [9]f i r s t
reported the results of a controlled, double-blind trial on the
efficacy of autologous bone marrow cell implantation. Both
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bone marrow nucleated cells for transplantation and con-
cluded that a concentrated BMA transplantation improved
femoral head preservation in the early stages of ONFH.
Our group developed a simple one-step concentration
procedure using a conventional manual blood bag centrifu-
gation technique instead of a cell separator [10]. This
procedure concentrates platelets in the BMA in addition to
bone marrow nucleated cells. We found that transplantation
of this product, a procedure named concentrated autologous
bone marrow aspirate transplantation (CABMAT), was able
to alter the natural history of ONFH [11]. In this
retrospective study, we have analysed the results of our
CABMAT study of patients with corticosteroid-induced
ONFH with SLE.
Materials and methods
All procedures were approved by an Institutional Ethics
Review Committee of the University of Tsukuba. Informed
consent was obtained from all individuals who participated
in this study prior to the operation.
Patients
Between April 2003 and May 2008, 85 patients (131 hips)
with ONFH were treated with CABMAT. Of the 131 hips, 76
hipsin42patients(49.4%)hadcorticosteroid-inducedONFH,
and 32 hips in 18 patients (42.9%) had corticosteroid-induced
ONFH with SLE. In this series, nine hips in six patients
(33.3%) with SLE, who had been followed for three years or
more, were examined retrospectively.
Table 1 displays patient clinical profiles. All subjects
were women with an average age at the time of CABMAT
of 31.5 years (range: 16–52 years). Among the six patients,
two had hyperlipidaemia and two had antiphospholipid
syndrome. The mean follow-up period was 41 months
(range: 37–53 months). Patients underwent follow-up
examination every three months after the CABMAT
procedure. The endpoint of evaluation was set as the time
point at which the patient required additional surgery (total
hip arthroplasty, THA).
Diagnosis of SLE and ONFH
All patients fulfilled the revised criteria for SLE established
by the American Rheumatism Association [12]. The
diagnosis, classification and staging of ONFH were based
on the 2001 Japanese Orthopaedic Association (JOA)
classification using anteroposterior (AP) and lateral plain
radiographs or magnetic resonance imaging (MRI) scans
[13]. Based on these criteria, necrotic lesions were
classified into four types by location on T1-weighted or
X-ray images. Type A lesions occupy the medial one third
or less of the weight-bearing portion. Type B lesions
occupy the medial two thirds or less of the weight-bearing
portion. Type C1 lesions occupy more than the medial two
thirds of the weight-bearing portion, but do not extend
laterally to the acetabular edge. Type C2 lesions occupy
more than the medial two thirds of the weight-bearing
portion and extend laterally to the acetabular edge. Staging
is based on AP and lateral views of the femoral head on X-
ray images. Stage 1 is defined as the period when there are
no specific findings of ON on X-ray images, although
specific findings are observed on MRI, bone scintigram or
histological examination. Stage 2 is the period when
demarcating sclerosis is observed without collapse of the
femoral head. Stage 3 is the period when collapse of the
femoral head, including crescent sign, is observed without
joint space narrowing. Stage 3 is divided into two sub-
stages. In stage 3A, collapse of the femoral head is less than
Table 1 Clinical profiles of patients
No. Sex Age
(years)
Follow-up period
(months)
Operated
side
Corticosteroid therapy Associated
disease
Classification
Before
CABMAT
After
CABMAT
Maximum dose
(mg/day)
Pulse Type Stage Type Stage
1 F 33 53 Bil 60 - HL C1/C2 1/2 C1/C2 2/2
2 F 33 52 Bil 1,000 + APS C2/C2 3B/2 C2/C2 3B/3A
3 F 52 45 L 1,000 + HL C2 3B C2 4
4 F 16 46 L 1,000 + - C1 2 C1 2
5 F 37 37 Bil 60 - - C2/C1 3A/2 C2/C1 3A/2
6 F 28 37 R 1,000 + APS C1 1 C1 2
F female, Bil bilateral, L left, R right, HL hyperlipidaemia, APS antiphospholipid syndrome
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greater. Stage 4 is the period when osteoarthritic changes
are observed.
Harvesting and concentration of bone marrow aspirates [10]
Under general anaesthesia, bone marrow was aspirated from
both anterior iliac crests using a bone marrow harvest needle
(Medical Device Technologies, Inc., Gainesville, FL, USA)
with 20-ml syringes prefilled with anticoagulant citrate
dextrose (1.5 ml) to prevent blood clotting. The contents of
each syringe were then transferred into a bag from the bone
marrowcollectionkit (Baxter,Deerfield,IL,USA).The BMA
was gravity-filtered through a series of mesh filters with
successively smaller diameters and then transferred to a
quadruplebloodbag(Terumo,Tokyo,Japan)forconcentration
using the manual blood bag centrifugation technique. The
fractionof bloodcontainingthe BMAwas processedby a two-
stepcentrifugationmethod(KUBOTA9800,Kubota,Japan)at
room temperature. After inverse centrifugation of the blood
bag at 1,200 g for ten minutes, the erythrocytes were
transferred into the satellite bag until the interface between
the plasma and the erythrocyte layer was 15 mm from the
bottom of the bag. Next, using high-speed centrifugation at
3,870g for seven minutes, plasma was transferred slowly into
a satellite bag until approximately 4 cm of plasma was left on
top of the buffy coat layer. This technique reduced the typical
300 ml of BMA to 40 ml to increase its nucleated cell
concentration. The time required for this two-step centrifuga-
tion was less than one hour.
CABMAT surgical procedure
Patients were placed in a supine position on a traction table
with a C-arm image intensifier. Before transplantation, we
typically made three multi-directional holes—central, ante-
romedial and posterolateral—by percutaneous drilling with a
Kirschner wire (diameter 2.7 mm) to perforate the interface
between the necrotic lesion and healthy bone. After the
intraosseous pressure of the femoral head was reduced by
drilling, core decompression was performed via the percuta-
neous technique with a 6.0-mm diameter trephine (Iso
Medical Systems, Tokyo, Japan). This instrument was
inserted into the centre of the necrotic site through the greater
trochanter. Its position in the femoral head and in the necrotic
site was monitored with biplane fluoroscopy and transplanta-
tion was performed slowly under fluoroscopic control.
Haematological analysis
Haematological analysis was performed according to a
previously published method [10]. The numbers of nucle-
ated cells in BMA were determined before and after
concentration with an automated haematology analyser
(K-4500, Sysmex, Kobe, Japan); the concentration ratio
was determined as follows: concentration ratio = number of
nucleated cells in BMA after concentration/number of
nucleated cells in BMA before concentration.
Clinical evaluation
Immediately before the procedure and at each follow-up,
patients were evaluated using the visual analogue scale
(VAS) for pain and the Harris Hip Score (HHS) [14]. The
VAS is an objective index for pain, where 100 mm
represents maximum pain, 50 mm represents intermediate
pain and 0 mm represents no pain. The HHS is an objective
index of hip joint function that quantifies the four
categories of (1) pain, (2) walking function and activities
of daily living, (3) extent of deformity and (4) joint range of
motion, with higher values indicating greater functionality.
Results were determined by the change in VAS and HHS
between preoperative evaluation and the most recent follow-
up evaluation. Clinical outcomes were categorised by HHS
results at the most recent follow-up as follows: excellent, 90–
100; good, 80–89; fair, 70–79; or poor, less than 70.
Radiographic evaluation
AP and lateral X-rays of the affected hip were taken at each
clinical evaluation. Radiographic progressions of the
femoral head collapse (pre-surgery to the most recent
follow-up) were evaluated in hips of each classification
and staging [13]. The degree of collapse was measured
using a template overlay of circles that increase in 1-mm
diameter increments. All radiographs were independently
evaluated by three different observers who were specialists
in orthopaedic surgery and authorised by the JOA.
Statistics
The concentrations of nucleated cells before and after the
concentration procedure were analysed using the paired t test;
VAS and HHS results before CABMAT and the most recent
follow-up evaluation after CABMAT were analysed using
the Mann-Whitney U test. Data are presented as mean ±
standard deviation (SD). A p value of <0.05 was considered
statistically significant.
Results
Patient characteristics
Table 1 shows the clinical profiles of patients. No patients
were lost to follow-up. Of the six patients studied, three had
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unilateral ONFH. Two of the six patients had been treated
with high-dose corticosteroid (at least 40 mg/day, or the
equivalent dose of prednisolone) and four of six patients
had received methylprednisolone pulse treatment.
Preoperatively, four of the nine hips were classified as
type C1 and five were classified as type C2. Two hips were
classified as stage 1, four hips as stage 2, one as stage 3A
and two as stage 3B. No donor site morbidity was observed,
and no infections, fractures, pulmonary embolism, or intra-
or postoperative neurovascular injuries were found. In
postoperative management, patients were non-weight-
bearing on the affected side for 2–12 weeks, after which
they gradually increased weight-bearing.
Haematological analysis
The mean nucleated cell count of the BMA was 0.99±
0.38×10
7 cells/ml before concentration and 5.32±2.08×
10
7 cells/ml after concentration; the mean concentration
ratio was 5.5±1.3. The number of nucleated cells in BMA
was significantly higher after our concentration procedure
(p=0.002; Fig. 1).
VAS
The VAS pain score was reduced immediately after the
CABMAT procedure in all patients. The mean VAS score
was 67±42 mm before surgery and 17±22 mm at the most
recent follow-up exam. The VAS score was reduced
significantly after CABMAT (p=0.02; Fig. 2).
Harris Hip Score
The mean HHS was 68±14 before surgery and 89±15 at
the most recent follow-up exam. The mean HHS was
improved significantly after the CABMAT procedure (p=
0.01; Fig. 3).
Clinical outcomes
Six hips were excellent, two hips were good and one hip
was poor as assessed by HHS. Patient 4 was a typical case
with an excellent clinical outcome (Fig. 4). THA was
necessary in one hip among the three hips operated on after
collapse (stage 3A and 3B). The hip (patient 3) was
classified as type C2 and stage 3B; the collapse progressed
from stage 3B to stage 4 9 months after CABMAT. The
patient suffered from continuous pain of the hip at
37 months post-surgery and THAwas performed 45 months
after CABMAT.
Radiographic progression after CABMAT
The relationship between the hip classification types or
stages before CABMAT and the progression of collapse
was evaluated: two of five type C2 patients, one of four
stage 2 patients, and one of two stage 3B patients
progressed (Fig. 5). Classification types that indicate
necrotic lesion size were unchanged between the preoper-
ative evaluation and the most recent follow-up in all of the
hips (Table 1).
Fig. 2 VAS: the mean VAS score was significantly reduced after
CABMAT (p=0.02)
Fig. 1 The number of nucleated cells (×10
7 cells/ml) in BMA
increased significantly after concentration (p<0.002)
Fig. 3 HHS: the mean HHS score improved significantly after
CABMAT (p=0.01)
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In this study, we evaluated the efficacy of CABMAT in
SLE patients who underwent corticosteroid therapy, a
population within which ONFH occurs with the greatest
frequency [3]. The results showed that CABMAT signifi-
cantly improved VAS and HHS results, and eight of nine
hips achieved a successful clinical outcome. These results
support the utility of CABMAT in preserving the femoral
head in patients with corticosteroid-induced ONFH with
SLE. However, one of nine hips required THA due to
progression of preoperative stage 3B to stage 4 (after
>3 mm collapse), osteoarthritis and continuous pain during
the 45-month follow-up period. These results are consistent
with previous studies showing late stage (post-collapse) at
presentation and large necrotic lesions in SLE as risk
factors for disease progression [15]. Thus, early detection of
ONFH in the pre-collapse stage is associated with an
improved and more favourable clinical outcome.
The prevalence of ON is much higher in SLE compared to
other clinical conditions that require chronic corticosteroid
therapy, suggesting that SLE-related features also contribute to
thedevelopmentofON[15]. Other reports have indicated that
the bone marrow microenvironment in SLE can potentially
injure osteoblasts and their progenitors, mesenchymal stem
cells (MSCs) [5, 15]; however, the exact mechanism by
Fig. 4 Representative radiographic images before and after CAB-
MAT. Before CABMAT (upper row), a band pattern was observed on
the X-ray (arrows) and changes in the bone marrow signal were
observed on MRI scans. Bone marrow oedema (BME) and joint
effusion (JE) were evident on an MRI T2-weighted image. The lower
row images were obtained during the 3-year follow-up evaluation.
Bone consolidation and reduction of the necrotic area were observed
on the X-ray and MRI images. Note that bone marrow oedema and
joint effusion have disappeared. AP anteroposterior, COR coronal
view, T1WI T1-weighted image, T2WI T2-weighted image
Fig. 5 Radiographic progres-
sion after CABMAT in each
classification type and stage
(n = no. of hips)
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necrosis is unclear. Recently, Hernigou et al. [16]s u g g e s t e d
that ONFH may be a disease of bone cells and/or MSCs.
MSC numbers and activity have been shown to be depressed
in both the haematopoietic and stromal compartments of bone
marrow in patients with ONFH. In addition, the number of
progenitor cells in patients undergoing corticosteroid therapy
was significantly lower than in patients who had a different
underlying aetiology [17]. To obtain optimal clinical results,
Hernigou et al. [8] suggested that more nucleated cells should
be transplanted than the average number of nucleated cells in
the femoral head (approximately 3.0×10
6/ml). For patients
whose bone marrow nucleated cell density is lower, they
suggested that bone marrow injection in combination with
growth factors could be a solution in the future.
In this series, nucleated cells were 5.5-fold more concen-
trated than pre-concentrated BMA and the mean number of
transplanted cells was 5.32±2.08×10
7 cells/ml. Thus, the
number of concentrated cells obtained using our centrifuga-
tion technique was much higher than the number of cells
suggested for optimal clinical outcome. In addition, the
concentrated BMA produced with our method is more
heterogeneous than BMA produced with the cell separator
method. We speculate that the BMA contains not only
osteogenicprogenitors, but also other types of nucleated cells,
platelet-rich plasma (a rich source of growth factors) [18].
Autologous MSCs appear to exhibit anti-inflammatory,
immunomodulatory and tissue-protective “trophic” effects
after transplantation for SLE [19]. These results indicate
that local transplantation of BMA could alter the patho-
physiological mechanisms of SLE in the necrotic site.
Additional studies are also needed to evaluate clinical
results through long-term follow-up.
Another possible mechanism for the therapeutic effect of
CABMAT is via core decompression with multiple drillings
[20]. Core decompression decreases the intraosseous
pressure and opens a channel into the necrotic area, which
is thought to alter the natural history of necrosis and
encourage revascularisation and repair. We drilled three
channels to induce migration of nucleated cells and
platelets to the necrotic site for bone regeneration [21].
The channels also reduced intraosseous pressure on the
femoral head and relieved the pain associated with ONFH-
induced bone marrow oedema or joint effusion.
In conclusion, we report on a minimum three year follow-
up of CABMAT for corticosteroid-induced ONFH with SLE.
In order to confirm the efficacy of CABMAT, results from
BMA transplantation carried out using our centrifugation
method or by a cell separator in a randomised, matched,
controlled prospective study need to be compared. This
technique required no special devices and may be an easy-to-
use, minimally invasive biological joint-preserving procedure
fortheearly stagesof corticosteroid-induced ONFH with SLE.
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